Angiotensin II type 1 receptor agonist antibodies (AT1R-AAs) have been associated with hypertension, atherosclerosis and vascular inflammation in human diseases. The aim of the study was to evaluate the prevalence of AT1R-AAs in active lupus nephritis (LN) patients and their association with vascular damage. One hundred and seven active LN patients underwent a complete clinical examination, measurement of AT1R-AAs, ambulatory blood pressure monitoring, carotid intima-media thickness measurement and morphometric analysis of subintimal fibrosis and medial hyperplasia of the vessels in the kidney tissue. Plasma AT1R-AAs were positive in 58 (54.2%) patients. The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, complement C3 and C4 levels and titers of anti-dsDNA antibodies were higher in the group with positive AT1R-AAs compared with those with negative AT1R-AAs. The AT1R-AA titers correlated with anti-dsDNA antibody titers and with complement C3 and C4 serum levels. In the kidney biopsy, the percentage of subintimal fibrosis and the area of medial hyperplasia were greater in the AT1R-AA-positive patients. No differences in arterial pressure, carotid intima-media thickness and response to therapy were detected. In conclusion, AT1R-AAs are prevalent in active LN patients and are associated with histologic features of microvascular damage.
DragunDCatarRPhilippeA. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int2016; 90: 280–288.
2.
WallukatGSchimkeI. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol2014; 36: 351–363.
3.
WenzelKRajakumarAHaaseH, et al.Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension2011; 58: 77–84.
4.
YangXWangFChangH, et al.Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens2008; 26: 1629–1635.
5.
LiWChenYLiS, et al.Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice. Am J Transl Res2014; 6: 678–690.
6.
DechendRGratzePWallukatG, et al.Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension2005; 45: 742–746.
7.
SunYZhangHWeiY, et al.The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension. Chin Med J (Engl)2008; 121: 43–48.
8.
WangBLiaoY-HZhouZ, et al.Arterial structural changes in rats immunized by AT1-receptor peptide. Heart Vessels2005; 20: 153–158.
9.
DechendRViedtCMüllerDN, et al.AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation2003; 107: 1632–1639.
10.
MengKZengQLuQ, et al.Valsartan attenuates atherosclerosis via upregulating the Th2 immune response in prolonged angiotensin II-treated ApoE(-/-) mice. Mol Med2015; 21: 143–153.
11.
ZhangWZhengYLiuF, et al.Mechanism of agonistic angiotensin II type I receptor autoantibody-amplified contractile response to Ang II in the isolated rat thoracic aorta. Acta Biochim Biophys Sin (Shanghai)2015; 47: 851–856.
12.
FuMLHerlitzHSchulzeW, et al.Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens2000; 18: 945–953.
13.
LiaoY-HWeiY-MWangM, et al.Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res2002; 25: 641–646.
14.
WallukatGHomuthVFischerT, et al.Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest1999; 103: 945–952.
15.
LaMarcaBWallaceKGrangerJ. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol2011; 11: 175–179.
16.
RossittoGRegolistiGRossiE, et al.Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. Hypertension2013; 61: 526–533.
17.
LiHYuXCicalaMV, et al.Prevalence of angiotensin II type 1 receptor (AT1R)–activating autoantibodies in primary aldosteronism. J Am Soc Hypertens2015; 9: 15–20.
18.
DragunDMüllerDNBräsenJH, et al.Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med2005; 352: 558–569.
19.
GiralMFoucherYDufayA, et al.Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant2013; 13: 2567–2576.
20.
SunYLiaoYYuanY, et al.Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen. J Am Soc Hypertens2014; 8: 21–27.
21.
WeiFJiaX-JYuS-Q, et al.Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart2011; 97: 479–484.
22.
HollanIMeroniPLAhearnJM, et al.Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev2013; 12: 1004–1015.
23.
BartelsCMBuhrKAGoldbergJW, et al.Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol2014; 41: 680–687.
24.
BjörnådalLYinLGranathF, et al.Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol2004; 31: 713–719.
25.
AhmadYShelmerdineJBodillH, et al.Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford)2007; 46: 983–988.
26.
Mejía-ViletJMCórdova-SánchezBMUribe-UribeNO, et al.Prognostic significance of renal vascular pathology in lupus nephritis. Lupus2017; 26: 1042–1050.
27.
CuevasEArreola-GuerraJMHernandez-MendezEA, et al.Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. Nephrol Dial Transplant2016; 31: 1738–1745.
28.
XiongJLiangYYangH, et al.The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract2013; 67: 1066–1067.
29.
González-AlmadaAArreola-GuerraJLopez-SanchezJA, et al.Pretransplant angiotensin II type-1 receptor antibodies point to an increase in renal graft subintimal fibrosis in living-donor kidney transplant recipients. Transpl Immunol2019; 54: 1–8.
30.
O’BrienEParatiGStergiouG, et al.European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens2013; 31: 1731–1768.
31.
TouboulPJVicautELabreucheJ, et al.Common carotid artery intima-media thickness: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study results. Cerebrovasc Dis2011; 31: 43–50.
32.
WeeningJJD’AgatiVDSchwartzMM, et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int2004; 65: 521–530.
33.
AustinHA3rdMuenzLRJoyceKM, et al.Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med1983; 75: 382–391.
34.
LefaucheurCVigliettiDBouatouY, et al.Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney Int2019; 96: 189–201.
35.
HillGSDelahousseMNochyD, et al.Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int2005; 68: 2288–2297.
36.
YuFTanYWuL-H, et al.Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus2009; 18: 1073–1081.
37.
DzauVJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertens2001; 37: 1047–1052.
38.
PhilogeneMCJohnsonTVaughtAJ, et al.Antibodies against angiotensin II type 1 and endothelin A receptors: relevance and pathogenicity. Hum Immunol2019; 80: 561–567.
39.
WassmannSStumpfMStrehlowK, et al.Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res2004; 94: 534–541.
40.
JonesSAFraserDJFieldingCA, et al.Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant2015; 30: 564–574.
41.
ZhangQReedEF. The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol2016; 12: 484–495.
42.
DechendRMüllerDNWallukatG, et al.AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin Nephrol2004; 24: 571–579.
43.
ValenteAJYoshidaTMurthySN, et al.Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Circ Physiol2012; 303: H282–H296.
44.
OhtsuHSuzukiHNakashimaH, et al.Angiotensin II signal transduction through small GTP-binding proteins. Hypertension2006; 48: 534–540.
45.
BalanescuSCalmacLConstantinescuD, et al.Systemic inflammation and early atheroma formation: are they related?Maedica (Buchar)2010; 54: 292–301.
GladmanDDGinzlerEGoldsmithC, et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
